NCT00509665 · OUTCOME

Overall Survival

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer · Source last updated 2018-07-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: From the time of initial therapy until the time of death.

Groups in this outcome

Gemcitabine+Doxorubicin

doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Gemcitabine+Doxorubicin	18

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Gemcitabine+Doxorubicin	5.6	Not reported	3.8	18.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3.8
upper Limit
18.2
value
5.6

denoms

counts
group Id
OG000
value
18
units
Participants

dispersion Type

95% Confidence Interval

groups

description
doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
id
OG000
title
Gemcitabine+Doxorubicin

param Type

MEDIAN

reporting Status

POSTED

time Frame

From the time of initial therapy until the time of death.

title

Overall Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice